August 6, 2009 (FinancialWire) — Dr. Joe Duarte (http://www.joe-duarte.com) recently noted: The Nasdaq Biotech ETF (NYSE: IBB) got a big boost a few weeks ago from a rally in shares of Human Genome Sciences (NASDAQ: HGSI), but the action on 8-5 may signal that reality is setting in, at least in the short term.

Duarte added: The rally in HGSI sparked a decent run for biotech, as it reminded investors that once in a while, a biotech company can make something happen which has the potential to both help patients as well as to make money. In the case of HGSI, a nice milestone was reached with a drug aimed at treating Lupus, a form of arthritis that attacks all body tissues, and can lead to inflammation of not just joints but also lungs, the heart, kidneys, and even the brain in a crisis stage.

Lupus patients are in pain most of the time and suffer from major organ system problems. Current treatments do little to stop the disease, only masking symptoms. In many cases the treatments are worse than the disease. HGSI’s drug, Benlysta, is aimed at blocking the substances that body cells produce that cause the inflammation that leads to the symptoms of Lupus. It’s the first new drug aimed at the disease in 50 years and has the potential to become a nearly $3 billion per year drug for HGSI and its partner Glaxo Smithkline.

Duarte’s conclusion: IBB had some tough sledding on 8-5, though, which suggests that a pullback of some sort may be in the offing.

Make sense of today’s nonsense. Get Doctor Joe Duarte’s Market I.Q., at:

http://www.joe-duarte.com/free/order_choices.asp and subscribe to www.joe-duarte.com, for its daily energy review and stock picks.

A book for this market - The All NEW Market Timing For Dummies. at: http://www.tinyurl.com/market-timing .

Duarte partners with the Investors Resource Center at Investrend Information (http://www.investrendinformation.com).

Duarte’s IntelligentForecasts.com (http://www.intelligentforecasts.com) provides free news coverage and analysis, and his daily articles and news summaries offer recommendations and analysis for ETFs, and individual stocks in the technology, health and biotechnology, and energy sectors. Duarte has combined expertise in health care, energy, and the effects of politics and global intelligence on the financial markets offer a unique blend of insight and information to thousands of active investors and political and intelligence aficionados around the world on a daily basis.

He is the author of: Futures And Options For Dummies, Successful Energy Sector Investing, Successful Biotech Investing and co-author of After-Hours Trading Made Easy. In early 2001, in Successful Energy Sector Investing, he correctly predicted that Venezuela’s political problems could lead to an energy crisis in the United States. He has also appeared as a weekly guest on Market Mavens Radio and has logged appearances on KNX radio in Los Angeles, Financial Sense.com radio, and Wall Street Radio.

One of CNBC’s original Market Mavens, Dr. Duarte has been writing about the financial markets since 1990. His articles and commentary have been featured on CBS Marketwatch, Barron’s, Smart Money, Medical Economics, and in Technical Analysis of Stocks and Commodities magazines. In 2003, Doctor Duarte received second place, in the professional section, of the Medical Economics Investment Challenge with a 12-month return of 42%.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.FinancialWire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@FinancialWire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.